Defining Binding Principles to Target Coactivator Med25-Activator Interaction by Foster, Nicholas
  








A dissertation submitted in partial fulfillment  
of the requirements for the degree of  
Doctor of Philosophy 
 (Chemical Biology)  






















Professor Anna Mapp, Chair 
Assistant Professor Amanda Garner 
Associate Professor Jolanta Grembecka 
















ORCID iD: 0000-0002-1034-6596 
 




First, I would like to thank Dr. Cherie Dotson. My serious thoughts of graduate 
school began while attending the Interdisciplinary Research Experience for 
Undergraduates (IREU) which she organizes through the College of Pharmacy. During 
that time, I was able to meet a group of great people who were also emerging scientists. 
Glad to still hear from some of them. One of the major highlights of that experience was 
being able to meet Dr. Evans. I was really surprised to talk to a scientist that knew the 
location my hometown and a lot about it.  
I’d also like to thank my research advisor Dr. Anna Mapp. While participating in the 
IREU summer program in 2014, I worked in her lab and began learning how to formulate 
questions and apply appropriate techniques to conduct sound, scientific experiments. I 
later joined Michigan and her lab. Thanks for your patience during my time working in 
your lab. Thanks for allowing me to join. 
I would also like to recognize my committee members - Professors Amanda 
Garner, John Montgomery, and Jolanta Grembecka. The recommendations and advice 
given by way of committee meetings helped me to grow academically and think outside 
of the box as a chemical biologist. 
Next, recognition is in order to my lab members. My lab members are a fun group 
to be around. It was exciting hearing the stories told most days in lab. Thanks also for 
iii  
being helpful resources when projects didn’t go as planned as well. Much success to you 
all. 
Lastly, I’d like to thank my family. My family is a very important part of me. Thanks 
to my parents and older brother for being a great support system while making it to this 
milestone. My father who was a diligent and hardworking man always kept me inspired. 
His consistency is something I always looked at as an example to pattern myself after. 
Rest easy pop, love you always. My mother is loving and supportive and keeps me 
grounded. She encourages me to never count myself out. I appreciate the things you do. 
I want to acknowledge my older brother. He always pushes me to do bigger and better 
things constantly. My family was very instrumental in giving me encouraging words during 
difficult points while working towards this goal. Also thanks to my friends and neighbors 
back home as well that always keep in contact and have uplifting conversations with me. 
My hope is that this will serve as an example to young ones from my neighborhood and 
hometown to show there are other ways to progress yourself outside of being an athlete 
or some sort of entertainer. GO BLUE !
iv  
Table of Contents 
 
 
Acknowledgements          ii  
 
List of Figures          vii 
 
List of Tables          ix 
 
List of Abbreviations         x 
 
List of Appendices          xi 
 
Abstract           xii 
 
 
Chapter 1. Targeting Therapeutically Relevant Mediator Tail Subunits 
 
1.1 Abstract           1 
 
1.2 The Components and Function of the Pre-Initiation Complex   1 
 
1.3 The Mediator Complex         4 
 
1.4 The Med25 Subunit         7 
 
1.5 The Challenge of Drugging Protein-Protein Interactions    9 
 
1.6 Thesis Summary         15 
 
1.7 References          16 
 
 
Chapter 2. Interrogating Coactivator Med25-Activator Interaction 
 
2.1 Abstract           22 
 
2.2 Introduction          23 
 
      Mediator Complex Subunit Med25       23 
 
v  
2.3 Results and Discussion        27 
 
      Dissection of Activator Binding Location      27 
 
      The Role of Electrostatics in Activator Interactions with Med25-AcID  29 
 
2.4 Conclusions          35 
 
2.5 Materials and Methods         37  
 
      Plasmids           37 
 
      Protein Expression and Purification       38 
 
      Peptide Synthesis         38 
 
      Direct Binding Experiments        40 
 
      Modeling Experimental         41 
 
2.6 References          42 
 
 
Chapter 3. Using Covalent Fragment to Target a Key Dynamic Substructure in 
Med25 
 
3.1 Abstract           47 
 
3.2 Introduction          47 
 
     Covalently Targeting Dynamic Proteins         47 
 
3.3 Results and Discussion        51 
 
Fragment Discovery in Med25 Using Disulfide Tethering    51 
 
Targeted Dynamic Substructure Allows for Allosteric Modulation   56 
 
3.4 Conclusions          59 
 
3.5 Materials and Methods         60 
 
3.6 Reference          62
vi  
Chapter 4. Conclusions and Future Directions 
 
4.1 Conclusions of this work        66 
 
4.2 Future Directions         70 
 
      Electrostatic Selectivity         71 
 
      Further Disulfide Fragment Assessment      71 
 


































List of Figures 
 
 
Figure 1.1 The Pre-Initiation Complex       2 
Figure 1.2 Structure of Mediator reported in literature     5 
Figure 1.3 The surface area-affinity relationship     10 
Figure 1.4 Techniques used for small molecule discovery for dynamic proteins 12 
 
Figure 2.1 The Mediator’s Subunit Med25      24 
Figure 2.2 Erm and ATF6a bind opposite surfaces in NMR studies   28 
Figure 2.3 Mutagenesis shows ATF6a engages the H2 binding surface  29 
Figure 2.4 Positive Residues of AcID & Negative Residues of Binding Activators 30 
Figure 2.5 The Hofmeister Series        31 
Figure 2.6 Salt anions change activator affinity      32 
Figure 2.7 Salt cation size changes activator affinity     33 
Figure 2.8. Erm soft mutations alter affinity      34 
Figure 2.9 Med25-Activator interaction binding model     37 
 
Figure 3.1 Tethering Schematic        48 
Figure 3.2 Disulfide Fragment Targets KIX dynamic structure    49 
Figure 3.3 Cartoon representation of Med25-AcID with the domain’s native   
       cysteine residues shown in red spheres     50
viii  
Figure 3.4  Med25-AcID native cysteine accessibility     51 
Figure 3.5  Results of the tethering screen with wild-type Med25-AcID and  
                  C506C mutant         54 
Figure 3.6 Fragment 22 alters activator binding to Med25    56 
Figure 3.7 Tethering efficiency of fragment 22 derivatives    57 




































List of Tables 
 
Table 1.1 Mediator’s Activator Binding Tail Subunits     7 
Table 1.2 Activation mechanism and associated phenotypes of listed  
                ETV transcription factor members      9 
Table 1.3 Coactivator Protein Inhibitors       13 
Table 2.1 The Net Charge of Activator Binding Proteins    26 









List of Abbreviations 
 
 
ATF6a Activation transcription factor 6a 
CBP  CREB binding protein 
DNA  Deoxyribonucleic acid 
DSF  Differential Scanning Fluorimetry 
Ets  E-twenty six 
ETV  Ets translocation variant 
GTF  General transcription factor 
Hif1a  Hypoxia inducible factor 1a 
KIX  Kinase inducible domain interaction domain 
Med25 Mediator subunit 25 
MLL  Mixed Lineage Leukemia 
MMP-2 Matrix Metalloprotease-2 
NR  Nuclear Receptor 
PPI  Protein-protein interaction 
RNA  Ribonucleic acid 
VP16  Herpes simplex virus protein 16 






List of Appendices 
 
Appendix A. Characterization of Synthesized Peptides    77 
 




Transcription is the process by which the information encoded in our DNA is converted to 
RNA. This important event is guided by an assembly of proteins brought together at 
specific gene promoter sites. A key part of the assembly is a coactivator complex called 
Mediator that interacts with transcriptional activator proteins. Mediator is therapeutically 
relevant because these interactions are misregulated in many diseases. Unfortunately, 
the coactivator class of proteins are notoriously difficult to target with druglike molecules. 
Coactivators are usually dynamic in nature and poorly understood mechanistically, 
making it quite challenging to design or discover small molecule modulators. Because of 
this, there is a lack of useful small molecule probes that target coactivators such as those 
within the Mediator complex.  
The coactivator Med25 is a component of Mediator that binds transcriptional 
activators using its Activator Interaction Domain (AcID) and there is considerable 
evidence that its network of protein-protein interactions (PPIs) are dysregulated in certain 
cancers. Although Med25 is conformationally dynamic like other coactivators, Med25-
AcID has a structurally unique fold. It contains a central β-barrel that is flanked by dynamic 
loop and helix substructures and the prevailing structural model is that the featureless 
surfaces of the b-barrel are the key binding surfaces for activators. This dissertation 
defines important binding mechanism principles for Med25-AcID and activator protein 
interactions that allow for small molecule probes. It was found using a series of binding 
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and mutagenesis structures that the activators ATF6a and ERM, despite sequence 
similarities, bind to opposite faces of the AcID b-barrel. Further computational and binding 
experiments revealed that charge-containing dynamic loop structures adjacent to the 
binding surfaces are important in these interactions. 
In Chapter 3, I report the successful targeting of one of the dynamic substructures 
in Med25 with a covalent disulfide fragment that influences the conformation and binding 
of Med25-AcID. This was accomplished through a mass spectrometry based Tethering 
screen used because of our lab’s previous success in targeting dynamic coactivator 
proteins. A disulfide fragment library was used to identify a lead fragment that changes 
the kinetic koff signature of two Med25-binding activators. Furthermore, the fragment 
stabilizes the AcID domain and uses a chiral surface that allows for sufficient disulfide 
exchange that may prove beneficial in changing activator binding effects. Taken together, 
results defined in this thesis will provide a framework to learning about coactivator-





















Chapter 1.  
 
Targeting Therapeutically Relevant Mediator Tail Subunits 
 
 
1.1 Abstract  
Transcription is the process whereby DNA is converted into RNA and is thus a critical 
step in gene expression. One important component of this process is the pre-initiation 
complex (PIC), a multi-protein complex that forms proximal to a gene just before the start 
of transcription. The assembly and function of the complex relies on a number of protein-
protein interactions (PPIs) that are valuable therapeutic targets due to their connections 
with disease. For example, misregulation of the PPIs formed between the Mediator 
complex’s tail module and transcription factors such as ETV1 and ERM are implicated in 
oncogenesis and metastasis in breast and prostate cancer. However, there have been 
challenges that have hampered drug discovery targeting transcriptional PPIs. In Chapter 
1, we outline the general working components of the PIC that help accomplish 
transcription, with a particular focus on Mediator and its constituent coactivator proteins. 
The importance of individual protein-protein interactions and their biophysical 
characteristics are also discussed. Lastly, commonly used strategies in targeting protein-
protein interactions are highlighted. 
 
1.2 The Components and Function of the Pre-Initiation Complex 
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Formation of the pre-initiation complex (PIC) is a key step in eukaryotic transcription, as 
it recruits and orients RNA polymerase II at the transcriptional start site. The minimal 
components of the pre-initiation complex include the general transcription factors (GTFs) 
TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH; the Mediator coactivator complex; and RNA 
polymerase II.20 The GTFs were first identified through fractionation of nuclear extracts to 
elucidate factors that allowed RNA polymerase II to transcribe DNA. Assembling in a step-
wise fashion, the GTFs orient the PIC and the polymerase (TFIID) as well as unwind and 
melt the DNA (TFIIH). It was subsequently found that a fully functional PIC also requires 
the Mediator complex, a transcriptional coactivator that forms protein-protein interaction 




Figure 1.1 The Pre-Initiation Complex. Components of the pre-initiation complex such as 
GTFs, coactivator complexes, and transcription factors are recruited to DNA help start 
gene transcription. Figure created in Biorender.com. 
 
The protein-protein interactions underpinning PIC formation are strictly regulated 
due to their fundamental role in gene expression. Post-translational modifications, 
subcellular localization changes, and phase separations all regulate the timing and 
location of PIC assembly. Dysregulation of the PPI network is thus associated with human 
diseases, from cancer to developmental disorders. For example, mutations in the TFIIH 
subunits p8 and p5210 alter interactions within the complex and are correlated with 
developmental disorders. In the case of TFIIB, mutations in the TBP subunit lead to 
spinocerebrellar ataxia and in Taf1 are linked to intellectual disabilities.12  Despite these 
connections with disease, the GTFs are not good targets for therapeutic discovery 
because they are required for transcription of nearly all class II genes.23  
As noted above, Mediator is a coactivator complex involved in the pre-initiation 
complex. This complex plays an important role with regard to the architecture of the pre-
initiation complex, as it forms a bridge between DNA-bound transcription factors and RNA 
polymerase II. More recent structural and functional data have revealed that individual 
subunits of Mediator (subunits 20-25) play roles beyond the architectural, however.26 The 
protein subunits that bind to transcription factors are of most interest from a drug 
discovery standpoint. Their transcription factor PPI networks are frequently dysregulated 






1.3 The Mediator Complex 
As a part of the pre-initiation complex, Mediator is involved in RNA polymerase II 
transcription. Before discovery of the Mediator complex, it was thought that the general 
transcription factors (TFIIA, IIB, IID, IIE, IIF, and IIH) along with polymerase II represented 
a complete transcription system.14 However, later work by Dr. Roger Kornberg identified 
the Mediator complex in yeast that appeared to interact directly with DNA-bound 
transcription factors. Early evidence of Mediator stemmed from squelching experiments. 
Squelching referred to the idea that overexpression of one activator affected the function 
of others due to activators competing for a common target. Kornberg and colleagues 
found that a crude fraction isolated from yeast was able to relieve squelching induced by 
the Gal4+VP16 activator and further fractionation revealed that the relevant component 
was Mediator.13  Decades of subsequent work led to the identification of 25 individual 
components of yeast Mediator while mammalian Mediator contains 33 subunits. There 
have been differences in the reported number of subunits that are present in the Mediator 
in literature.6 This complex transfers information from DNA-bound transcription factors to 
the GTFs and polymerase II assembly through protein-protein interactions. It has roles in 
polymerase II C-terminal domain (CTD) phosphorylation as well.  
Structurally, Mediator is divided into the head, middle, tail, and kinase modules, 
where the Med14 subunit stabilizes its assembly (Figure 1.2). El Khattabi et al. report 
cryo-EM studies of mammalian Mediator at 5.9 Å. The head and middle modules in the 
5.9 Å structure were identified based upon homology to the S. pombe Mediators, while 
some of the tail module was identified through deletion and mass spectrometry-based 





Figure 1.2 Structure of Mediator reported in literature. (A) shows the head (Red), Middle 
(Blue), and Tail (Yellow) reported at angles rotated at 90o angles. (B) The subunits are 
compartmentalized by sections of the Mediator. This figure was used with the permission 
of publisher. 
 
The Mediator complex has an important role in the architecture of the PIC by bridging 
transcription factors to the general components required for basal level transcription. 
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Outside of this, it has other functions. RNA-Sequencing (RNA-Seq) studies of Mediator-
depleted cells show there is a ~7-fold downregulation of the transcriptome.9 The head 
and middle modules, which is considered the “core Mediator”, interacts with RNA 
polymerase II and are critical for regulated transcription. The tail module has 
exchangeable subunits that can vary depending on context. 
The tail module is segmented into two connected sections.  One comprises the upper 
portion, which is smaller in size and closest to the head module which is more 
architectural module. The second is the larger that is ~380 kDa in size. Experiments with 
knockout tail subunits showed slight changes to polymerase II activity while, the opposite 
effect was seen with head and middle module knockout experiments. There are specific 
subunits in the larger tail module like Med15, Med 23, and Med25 that are known to 
interact with transcription factors and especially transcriptional activators. For example, 
yeast Med15 is known to bind to Gal4, Gcn45, and VP16 activators.29 The Arc105/Med15 
subunit in humans complexes with SREBP transcription factors and in doing so regulates 
lipid homeostasis.35 And, as outlined in more detail in the subsequent section, Med25 
forms PPIs with the ETV/PEA family of ETS transcription factors as well as the stress-
response transcription factor ATF6a.32,25,15,3 The coactivator subunits of the tail are also 
known to be associated with a number of diseases. Subunits such as Med23 are good 
examples. Loss of the metastasis suppressor gene KiSS-1 is heavily involved in cancer.22 
Studies have shown KiSS-1 gene expression in metastasis is regulated through 
specificity protein-1 and its interaction with Med23. Other components of the tail module 




Table 1.1 Mediator’s Activator Binding Tail subunits  
Activator-Binding Tail Subunits Activators 
Med15/Arc105 GCN4, Pho4, Msn2 24, lno2, VP16, Pdr1, 
SREBP 
Med23 Elk1 27, Elf3 2, Sp1 
Med25 VP16, Erm, ETV1, ETV4, ATF6a, p53 17, 
cJun 
 
1.4 The Med25 subunit 
The Med25 subunit of the tail module contains at least three protein-protein interaction 
domains. They are the von Willebrand factor A (VWA), activator interaction domain 
(AcID), and nuclear receptor box (NR). The VWA domain binds the rest of Mediator 
complex, and AcID interacts with activation regions of transcription factors. The last 
domain is located in the C-terminal region and binds nuclear receptors. Med25 has been 
shown to regulate drug and lipid metabolism through HNF4a genes, where HNF4a is in 
the class of orphan nuclear receptors. 
As shown above, Med25 has domains designated for interacting with different 
partners. The Med25-AcID and transcription factor binding event is preferred because the 
activation domain of transcription factors allow for studying a particular set of 
therapeutically relevant genes outside of the GTF’s large range of genes. Med25-AcID 
alone binds many different transcription factors. It is able to bind the ETV family 
transcription factors. The subfamilies ETV1, 4, and 5 bind with an affinity of ~500 nM. 
These activators use a 30-residue binding region (the transcriptional activation domain).7 
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Overexpression of the Med25-AcID or the VWA domain inhibits ETV-mediated 
transcription of reporter genes in a range of promoter contexts (Table 1.2). It also interacts 
with the herpes simplex virion protein 16 (VP16). VP16 controls the transcription of 
immediate early viral genes.33,28 Other transcription factors such as ATF6a binds as well, 
and it is involved in endoplasmic reticulum stress response.  
Med25-AcID is considered a hub motif because it can bind a variety of different 
binding partners using two conserved binding surfaces. In addition, there is also no crystal 
structure available due to its’ dynamic characteristics. Early NMR structural work carried 
out, showed Med25-AcID has a b-barrel framed by flexible substructures. Questions 
immediately rose pertaining to its binding mechanism seeing its drastically different to 
other better studied coactivators such as CBP KIX. Learning about Med25-AcID binding 
mechanism will help guide small molecule discovery seeing there has been lacking 
information. It will also allow us to extract guiding principles that can then be compared 
to common coactivator transcription factor interacting networks. Lastly, it allows us to 





















1.5 The Challenge of Drugging Protein-Protein Interactions 
Although protein-protein interactions are sought after drug targets, there are limitations in 
discovery. Protein-protein interactions, unlike enzymes, often do not have well-defined 
binding cavities. The surface area plays an important role in protein-protein interactions, 
with surface areas ranging from 500Å2 to greater than 5000Å2.This category of 
interactions have a range of binding affinities. For example, the CBP-KIX domain, a 90 
residue domain, has a small surface area and binds the c-Myb transactivation domain 
with low binding affinity in the single-digit micromolar range. In contrast, the MDM2 protein 





Figure 1.3 The surface area-affinity relationship. Protein-protein interactions’ surface 




Another difficulty of targeting protein-protein interactions is that many lack 
topology. In the case of Med25-AcID, the original structural studies suggested that the b-
barrel has the bulk of the contacts with cognate transcriptional activators and this surface 
is not only large but largely featureless. In other words, there are not binding grooves or 
clefts that could accommodate small molecules. An additional complication is that 
coactivators such as Med25 are involved in forming short-lived contacts where the 
dynamic characteristics of the protein accommodate this binding event. The dynamic 
regions usually include disordered loop regions and helix substructures which are thought 
to contribute to allosteric communication effects in protein-protein interactions. This as a 
result that makes small molecule discovery difficult. 
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There are emerging technologies that have been used in targeting dynamic 
proteins. Techniques such as mass spectrometry, NMR, and fluorescence based 
methods are examples that have been used to identify small molecule modulators.11 
Identifying small molecule modulators are probes that bind proteins that cause allosteric 
effects. Allosteric modulators are particularly desirable for dynamic proteins such as 
coactivators because of their ability to capture different conformational states. This is 
useful because coactivators can bind with more than one partner and adopt 
conformations useful in expressing appropriate genes. Allosteric  modulators thus will be 
powerful tools to regulate gene expression in disease states. For these reasons,  
screening or analysis methods that enable detection of conformational changes in the 
protein are particularly useful for identifying allosteric modulators of coactivators. 
Heteronuclear single quantum coherence (HSQC) NMR spectroscopic methods 
can be used to detect conformational changes induced by small molecules by measuring 
chemical shift changes in the amide backbone or in particular side chains. Collision 
Induced  Unfolding (CIU) involves Ion Mobility Mass Spectrometry (IM-MS) which rapidly 
detects conformation of proteins based upon stability and unfolding patterns by 
monitoring ions in gas phase. This method produces intensity fingerprints that are then 
compared between protein species. Lastly, differential scanning fluorimetry (DSF) reports 
on the conformation of proteins as well.34 A fluorescent dye is incubated with your protein 
species of interest. The sample is then heated over a range of temperatures and the dye 
binds as temperature rises accompanied by protein unfolding. This in turn increases 
fluorescence signals. Thus, if a small molecule alters the stability of the protein of interest, 
this will be detected by a change in the observed melting temperature in DSF. While all 
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of these are valuable methods for studying dynamic proteins such as coactivators, it is 
only DSF that is easily formatted for high throughput screening. And, unlike the first two 
methods, structural models can only be obtained by follow-on experiments.  
 
 
Figure 1.4 Techniques used for small molecule discovery for dynamic proteins. (A) 
Collision-induced unfolding method maps structural changes by mass spectrometry. (B) 
NMR Methods monitors conformational changes caused by small molecules with protein 
backbone shifts. (C) DSF monitors small molecules ability to stabilize proteins of interest. 
This was used with the permission of the publisher. 
 
There are examples in which research groups have shown successful small molecules 
that target dynamic coactivator protein-protein interactions. The CBP/p300 master 
coactivator complex has more than one activator binding domain that has been targeted.8 
The KIX domain of the complex is capable of binding more than one activator using two 
surfaces. Natural products have yielded inhibitory effects when KIX is bound to activators 
MLL and pKID. Sekikaic acid which is a part of the depside family, produces these 
 
13 
results.18 The c-Myb activator can bind KIX as well, and it is implicated in the development 
of leukemia. Naphthol inhibits c-Myb activity in vitro and in vivo.30 Other domains such as 
Taz 1 have been targeted with inhibitors such as OHM116 and KCN136. These target the 
HIF1a-Taz1 interaction. These molecule serve as an example in the field that show some 
of the limited amount of small molecule inhibitors and the need to better understand the 
underlying principles of coactivator molecular recognition.4 
 
Table 1.3 Coactivator Protein Inhibitors 
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1.6 Thesis Summary 
The goal of this thesis work is to identify key principles of how Med25 interacts with 
binding partners and to identify small molecule fragments that target the coactivator. As 
outlined in Chapter 2, a study was carried out to define key binding characteristics of the 
Med25-AcID activator interaction. This was done by initially using fluorescence 
polarization and site directed mutagenesis to determine the binding sites of AcID’s 
interacting activators. This was then followed by defining the contributions of 
electrostatics through salt changes and activator peptide mutations in maintaining binding 
affinity. The substructures of AcID were thought to be important players in activator 
recognition as a large number of charged residues are localized in these regions. This 
was further confirmed by molecular dynamic simulations. Described in Chapter 3, building 
from this theme a small molecule fragment library was screened against AcID using the 
Tethering technique. It was performed in a manner that isolated hits specific to the 
dynamic loop substructure of AcID. The screen yielded a fragment that stabilizes the AcID 
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domain that could be important in regulating binding activators which has been seen in 
literature with another coactivator protein.  
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Transcriptional coactivators are highly dynamic proteins that assist in the initiation of gene 
expression. The hub protein and coactivator Med25 has the ability to recognize many 
different transcription factors as part of its role in transcriptional initiation. It has been 
shown to associate with transcription factors such as herpes simplex virus VP16 (viral 
infection), Erm (cancer metastasis), and ATF6a (unfolded protein response). It also 
contains a unique structural fold in comparison to other coactivator proteins. Most 
coactivator proteins contain a helix bundle motif, while Med25 uses a stable b-barrel core 
flanked by helix bundles and flexible loop regions. Thus, a key question in the field has 
been if the uniquely folded Med25 Activator Interaction Domain (AcID) protein-protein 
interactions form via mechanisms distinct from the canonical coactivator structures. 
Chapter 2 outlines our findings that electrostatics and dynamic substructures are 
essential for the affinity and specificity of Med25’s interaction with Transcriptional 
Activation Domains (TADs). This data shows the activator ATF6a and Erm bind in 
 
1 Portions of this chapter are from “Conservation of coactivator engagement mechanism enables 
small-molecule allosteric modulators” A. R. Henderson, M.J. Henley, N. J. Foster, A.L. Peiffer, 
M.S. Beyersdorf, K.D. Stanford, S. M. Sturlis, B. M. Linhares, Z.B. Hill, J. A. Wells, T. Cierpicki, 
C. L. Brooks III, C.A. Fierke, A. K. Mapp. Proc. Natl. Acad. Sci. USA 2018 115, 8960-65.  
 
23 
different locations; charged residues of this coactivator-activator complex maintain 




Mediator Subunit Med25  
The Med25 subunit is a part of the tail region of the Mediator coactivator complex (Figure 
2.1A). This subunit is composed of three domains (Figure 2.1B). The VWA domain 
located on the N-terminus interacts with the other subunits of the Mediator complex. The 
C-terminus contains the motif LXXL noted for binding nuclear receptors such as the 
retinoid receptor. The activator interaction domain (AcID) binds different transcription 
factors and in this way Med25 can bridge transcription factors and the overall Mediator 
complex.   The AcID domain uses two binding sites labeled the H1 and H2 face to engage 
transcription factors (Figure 2.1C). Although there are no crystal structures of Med25-
AcID, there are reported NMR structures of the AcID domain.1 Such structural information 





Figure 2.1 The Mediator’s Subunit Med25 (A) Mediator structure that highlights the tail 
region that contains Med25.7 . (B) The three domains of Med25 are displayed (C) The 
Activator Interaction domain’s two binding surfaces. 
 
Through its ability to engage with a variety of activator binding partners by way of AcID, 
Med25 regulates a diverse set of genes. Activator ERM, which belongs to the PEA3 
subfamily of Ets transcription factors, complexes with AcID to regulate matrix 
metalloprotease protein-2 (MMP-2) that is involved in cancer metastasis.11,25,5 ATF6a is 
another prominent transcription factor that is dependent upon AcID for function, in this 
case upregulation of the cellular stress response.18 Perhaps the best studied binding 
partner is the viral activator VP16, a protein from herpes simplex that hijacks coactivators 
such as Med25 to upregulate the immediate-early viral genes upon infection.9 
 VP16 was the first binding partner characterized in complex with Med25. VP16 
contains an approximately 50 residue transcriptional activation domain that it uses to 
complex with coactivators.14,26 In the case of Med25-AcID, two studies published 
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simultaneously in 2011 showed that the VP16 activation domain wraps around the b-
barrel, contacting both binding surfaces within AcID. As later shown by our lab and others, 
the N-terminal and C-terminal halves of VP16 can bind independently to AcID. The N-
terminal half is termed VP16H1 and engage one surfaces the appropriately named H1 
binding surface of AcID. Conversely, the C-terminal half called VP16H2 interacts with the 
H2 Med25-AcID binding surface (Figure 2.1C). Subsequent NMR studies by Verger and 
co-workers revealed that the ERM transcriptional activation domain interacts with the H1 
surface. However, although the Med25-AcID dependence of ATF6a was well-
established, the location of its binding was not known. Thus, there were questions as to 
the relevance of the H2 binding surface.  
 
A notable aspect of Med25 AcID-activator complexes is their relatively high 
affinity.13 For example, the well-studied KIX motif of the coactivator CBP interacts with its 
cognate activators with KDs ranging from 1-100 µM whereas Med25 activator KDs are in 
the nanomolar regime (VP16: 60 nM; ERM: 590 nM).8 Affinity and specificity for activator-
coactivator complexes are typically attributed to interactions between hydrophobic amino 
acids, as well as hydrogen bonding. For example, mutation of Trp57 in ERM reduces 
affinity for AcID >10-fold. There are indications that electrostatic interactions may also 
play a role in binding strength. Med25-AcID is overall positively charged (7.2) and the 
positively charged residues are largely located in the flexible loop regions (Table 2.1). 
Other known coactivators are positively charged as well. Conveniently, the activator-
binding partners are amphipathic and negatively charged. For example, the Taz1 domain 
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of CBP coactivator complex is +10.2 in charge while its complementing binding activators 
HIF1-a and CITED2 are -5.1 and -7.27,3,4 Further, in this latter example, the electrostatic 
contacts are important for essential allosteric communication between binding sites.21,19 
For these reasons, we hypothesized that electrostatic contacts might play an important 
role in affinity and perhaps specificity of Med25 AcID-activator complexes.   
 
Table 2.1 The Net Charge of Activator Binding Proteins 
Activator Binding 
Domains (ABDs) 
Net Charge PDB 
Med25 AcID 7.2 2XNF 
CBP Taz 1 10.2 1U2N 
CBP Taz 2 18.9 3IO2 
CBP KIX 3.5 4I9O 
TBP 15.9 1CDW 
CBP IBiD 5.0 1ZOQ 
 
 
The misregulation of the Erm-Med25 AcID and ATF6a-Med25 AcID PPIs are implicated 
in breast and prostate cancer. Despite considerable interest in these PPIs, however, there 
were no reported synthetic modulators. Med25-AcID in particular is challenging to target 
due to the large, featureless binding surfaces with which the activators interact and the 
lack of a more molecular-level understanding of how they interact. Further, although we 
and others have found that in the case of helical coactivators the loop regions are 
especially important for molecular recognition, literature data suggested that this might 
not be the case for Med25 due to its distinct structure.6,20 So, the goal in the work of this 
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chapter was to test if electrostatics and dynamic substructures were similarly important 
for Med25 as displayed in other coactivator-activator binding events.   
 
2.3 Results & Discussion 
 
Dissection of Activator Binding Location 
 
Coactivators bind intrinsically disordered transactivation domains that are heavily 
involved in disease.24 Disordered activator regions interact on separate surfaces within 
coactivator hub proteins that communicate to express a desired gene. Med25-AcID was 
previously shown to have discrete binding surfaces labeled H1 and H2. In addition, VP16 
and Erm were known to bind both surfaces in a particular location, but it was unknown 
where ATF6a bound within the domain. To address this, we used a combination of 
mutagenesis and binding experiments to uncover where activator ATF6a binds on the 
protein. 
First, to identify the binding site of ATF6a, we measured the chemical shift changes 
in each activator-AcID complex via 1H, 15N-HSQC NMR titration experiments with 
ERM(38-68) and ATF6a(40-66) in the presence of 15N-labeled Med25 AcID. The amide 
proton perturbation patterns measured for the activator•AcID complexes suggest a 
different binding mode for ERM and ATF6a. ERM binding predominantly led to 
perturbations at residues on the H1 surface of AcID, in agreement with the model in which 
it preferentially interacts at that site. In contrast, interaction with ATF6a lead to significant 
chemical shifts changes on the H2 binding surface. ATF6a-induced shifts of residues 
Q456, M470, and H474 which were also affected to varying degrees by VP16 and largely 





Figure 2.2 Erm and ATF6a bind opposite surfaces in NMR studies. Results of chemical 
shift perturbation experiments superimposed upon the Med25-AcID structure (PDB 
2XNF). Residues displaying chemical shift perturbation greater than 2 SD upon Erm and 
ATF6a binding are depicted in rust and yellow spheres. Experiments were done by Dr. 
Andrew Henderson and Dr. Brian Linhares. 
  
Consistent with ATF6a and ERM interacting on opposing sides of AcID, mutations 
introduced on one or the other of the binding surfaces produced distinct effects. H1 
mutations R538E, K411E, and Q451E inhibit ERM binding while ATF6a is largely 
unaffected. In contrast, H2 mutations R466D and M523E significantly inhibit ATF6a with 
minimal impact on ERM binding. Taken together these data indicate that ATF6a binds on 
 
29 
the H2 binding surface of Med25-AcID, opposite the site of ERM. Further, the distinct but 
overlapping chemical shift patterns observed upon binding of each of the activators to 
Med25 suggest several unique binding modes accommodated within AcID. This is 
analogous to helical activator binding domains such as GACKIX of CBP/p300, a three-




Figure 2.3 Mutagenesis shows ATF6a engages the H2 binding surface. Results of direct 
binding experiments with fluorescein-labeled activators and the indicated mutants of 
Med25 AcID as measured by fluorescence polarization expressed the fold change relative 
to the dissociation constant of each activator for the WT AcID.  The indicated error is 
propagated from three independent dissociation constant measurements. Binding 
experiments were carried out collaboratively by Dr. Andrew Henderson, Nicholas Foster, 
Dr. Matthew Beyersdorf, Kevon Stanford, and Dr. Steven Sturlis. 
 
The Role of Electrostatics in Activator Interactions with Med25-AcID 
As outlined in the Med25 AcID has a large number of positive charged residues located 
within the domain (Figure 2.4 - top). These residues are mostly located in its dynamic 
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loop and helix substructures. The loop regions of the domain contain 10 positive charged 
residues, where 5 (K411, K413, K422, H502, and R509) are on the H1 face and 3 (K518, 
K519, and K520) on the H2 face. The remaining 2 (H435 and K440) are in the loop region 
spanning the bottom of the domain. The β-barrel has only 4 positive residues (R425, 
K447, H474, and H499). In contrast, its binding activators are most negatively charged 
(Figure 2.4 - bottom). AcID’s binding activators have a net charge that ranges from -7 to 
-13.9. These characteristics suggest that electrostatic contacts are important for 
transcription factor binding to Med25 and could also contribute to selectivity relative to 






ERM38-72 DLAHDSEELFQDLSQLQEAWLAEAQVPDDEQFVPD -10.9 
ATF6⍺40-66 DTDELQLEAANETYENNFDNLDFDLDL -10 








Figure 2.4 Positive Residues of AcID and Negative Residues of Binding Activators. (top) 
shows the positive residues of the Med25-AcID shown in red.(bottom) shows the 
sequence and net charge of binding activators. 
 
The most common strategy to test the role of electrostatic interactions in binding is to 
change the nature and concentration of salt present in buffer solutions. Salts within 
buffers are able to interact directly and indirectly with proteins in solution with varying 
strength, depending on the nature of the constituent ions and their concentration. The 
Hofmeister series of cations and anions was originally identified from studies of protein 
precipitation and unfolding10.  More recent studies have revealed that in many cases ions 
can bind charged side chain residues of a protein or peptide, producing a shielding effect 
that thus can affect binding (Figure2.5). 
 
Figure 2.5 The Hofmeister Series. Starting from the left identifies the poor binding ions 
of proteins and ions furthest to the right show the best binding ions of proteins 
 
 After considering the Hofmeister series, binding experiments were first carried out that 
increased the concentration of sodium chloride in the assay buffer.15,16 Standard binding 
assay buffer contains 100 mM sodium chloride which is close to normal cell 
concentrations and 10 mM sodium phosphate. Thus, if electrostatic interactions play an 
important role in binding then higher sodium chloride concentrations should decrease the 
stability of the complex and binding affinity. Med25-AcID binds the activator peptide 
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Erm38-72  with an KD value of 0.2 µM and this decreases affinity 10-fold. The activator 
peptide VP16aH2467-488  interacts with the opposite face (H2) and shows a 6.4-fold 
decrease upon increasing NaCl concentrations to 400 mM. In contrast, the presence of 
100 mM NaF shows minimal change in binding affinity of activator VP16aH2 467-488.Thus, 
electrostatic interactions at both the H1 and H2 binding surfaces appear relevant. 
 
 100 mM NaCl 400 mM NaCl 
ERM38-72 0.2 ± 0.04 2.0 ± 0.2 
VP16437-488 0.5 ± 0.03 3.2 ± 0.3 
 
 
Salts KD Values (µM) 
100 mM NaCl 0.3 ± 0.05 
100 mM NaF 0.2 ± 0.02 
 
























































Figure 2.6 Salt anions change activator affinity. Measurements were taken in 
fluorescence polarization experiments. Each value is the average of at least three 
independent binding experiments with the indicated error (SDOM). 
 
The size of ions was considered as well. There is a correlation between the size of the 
shielding ion and its effect on activator binding. Other salts were used in comparison to 
NaCl. MgCl2 was used because it produces divalent Mg2+ ions that bind better to 
negatively charged residues than Na+. The presence of MgCl2 decreases VP16aH2 467-
488  binding by 13-fold indicating that it is better shielded by MgCl2 and, further, that the 
negatively charged residues of the activator peptide  play a key role in the affinity for 
Med25 AcID.   
 
Salts KD Values (µM) 
100 mM NaCl 0.5 ± 0.03 
200 mM NaCl 1.1 ± 0.1 
100 mM MgCl2 13.0 ± 5.0 
 
Figure 2.7 Salt cation size changes activator affinity. Measurements were taken through 
fluorescence polarization experiments. 
 
To further understand how electrostatics guide interaction, point mutations were 
implemented within the activator peptide of ERM38-68 and binding affinities were 




















measured. This included mutating the negatively charged glutamic acid residues of the 
sequence to glutamine residues. This reduces the peptide charge from -9.9 to -4.9. The 
affinities were lowered by 2-fold. 
 
 
 KD Values (µM) 
ERM38-68 0.53 ± 0.08 
ERM38-68  E - to -  Q 1.0 ± 0.3 
 
 
Figure 2.8. Erm soft mutations alter affinity. All glutamic acid residues were mutated to 
glutamine residue. Binding experiments were measured through fluorescence 
polarization. 
 
Taken together, these data demonstrate that it is not just hydrophobic interactions that 
contribute to Med25-activator interactions. Further, they are key at both the H1 and H2 
binding surfaces. Increases in salt concentration inhibited binding for both ERM and the 
H2-binding half of VP16. This was further confirmed by soft mutations within ERM that 
removed charge and led to a 2-fold attenuation in binding affinity for Med25. These results 






outside the b-barrel binding surfaces that are reported to be the primary contacts for 
activator-binding surfaces.  
 
2.4 Conclusions 
Perhaps the most significant results that emerged from the studies in this chapter 
is the influential role of electrostatic contacts on the strength of Med25 AcID-activator 
complexes. As shown the second half of the work, activators that bind to either the H1 
(ERM) or H2 (VP16(467-488)) are impacted significantly by either neutralizing mutations 
or increasing salt concentrations. This was somewhat surprising because the canonical 
view of activator-coactivator complexes is that they are driven by hydrophobic contacts 
and because the previously identified activator binding surfaces of Med25-AcID are 
largely hydrophobic, with the charged residues residing on adjacent loops and helices. 
To address this conundrum, colleague Amanda Peiffer carried out a computational study 
of activator-Med25 AcID complexes to develop a structural model. To do this, all-atom 
molecular dynamics simulations were carried out using implicit solvent models (GBSW) 
and with temperature replica exchange in CHARMM.22 Simulations were performed on 
both unbound Med25-AcID and a model of this protein in which the VP16(438-454)G450C  
is covalently linked at C506. To identify the substructures most stabilized upon binding, 
the root-mean-square fluctuations (RMSF) for each residue were calculated from the 
resulting trajectories (Figure 2.9A and 2.9B). In these figures, the line color reflects the 
range of motion of each residue. In the unbound structure (Figure 2.9A), the b-barrel core 
is relatively static whereas the loops and helices framing the two binding sites show 
particular mobility. The presence of VP16(438-454) significantly alters the extent of 
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motion (Figure 2.9B). Particularly notable is that the upper loop on the H1 binding surface 
(residues 409-424 of Med25) appears to strongly interact with VP16. Supporting this 
model is the effect of mutations within this region on another H1-binding activator, ERM; 
a K411E mutation, for example, resulted in 4-fold weaker ERM binding (Fig. 2.3). The 
loop at the lower portion of this binding interface (residues 435-446) is also significantly 
altered upon interaction with VP16 and, again, interaction with H1 face-targeting ligands 
such as ERM is altered upon mutation at this site. The helices flanking the H1 binding 
surface also undergo significant stabilization upon binding, suggesting that they also play 
an important role in the defining the binding site. An analysis of RMSDs of residues in 
Med25-AcID unbound to any ligand reveals that the most dynamical regions of the protein 
are indeed the loops, with significant motion in the flanking helices as well, consistent with 
the preliminary structural model. Taken together, this model serves as a framework for 




Figure 2.9 Med25-Activator interaction binding model. (A,B) The NMR coordinates for 
Med25 AcID (PDB 2XNF) were used to construct the initial structure of Med25 in 
CHARMM using the Multiscale Modeling Tools for Structural Biology (MMTSB).  For (B) 
VP16(438-454) G450C was constructed in CHARMM as a helical peptide23, which was 
then patched in CHARMM to Med25 C506 through the formation of a disulfide bond at 
C506 (transparent blue helix). Using GBSW implicit solvent2, temperature replica 
exchange was implemented using the CHARMM22 force field12. The root mean square 
fluctuations (RMSF) were calculated for each Med25-AcID residue by overlaying Ca 
atoms for all of the coordinate files produced from the simulations.17 In this representation, 
the coloring correlates with the degree of dynamical behavior of each region. MD 
simulations done by Amanda Peiffer. 
 
 
2.5 Materials and Methods 
 
Plasmids 
The plasmid pET21b was used to produce the apo Med25(394-543) with a six histidine 




Protein Expression and Purification 
Med25-AcID protein was transformed into BL21-AI competent cells. Ampicillin and 
streptomycin LB Agar plates were streaked  and incubated at 37oC overnight. The next 
day, a 50 mL Terrific Broth (TB) starter culture with 5µL ampicillin (100mg/ml) and 
streptomycin (50mg/ml) was grown overnight with a picked colony from the LB plate at 
37oC as well. The next morning,  7mL were used to inoculate the 1 liter TB that contained 
ampicillin and streptomycin. The bacteria was grown at 37oC to an OD600 of 0.8. Once 
optimal OD600 was achieved, 10% arabinose and IPTG was added and incubated at 27oC  
at 250 rpm overnight. The 1 liter TB culture was spun down to pellet using the floor 
centrifuge at 5000 rpm for 20 minutes at 4oC. Cell pellets were stored at -80oC. Cell pellet 
was resuspended in lysis buffer (components), b-mercaptoethanol, and an EDTA-free 
protease inhibitor tablet. The suspended cells were sonicated and filtered before 
purification. Sample was purified by FPLC with both Nickel (HisTrap, Buffer A: 50mM 
sodium phosphate, 300mM NaCl, and 30mM imidazole, pH 6.8  ; Buffer B: 50mM sodium 
phosphate, 300mM NaCl, and 400mM imidazole, pH 6.8) and Ion Exchange columns 
(Buffer A: 50mM sodium phosphate, 1mM DTT, pH 6.8 ; Buffer B: 50mM sodium 
phosphate, 1mM DTT, 1M NaCl, pH 6.8 ). Purified samples were collected and dialyzed 
in 10 mM sodium phosphate and 100 mM sodium chloride. The concentration of the 
resulting Med25 was measured using a Nanodrop at wavelength 280 nm using the 





Peptides were synthesized on Rink amide resin using standard FMOC solid-phase 
synthesis methods on a Liberty Blue Microwave Synthesizer (CEM). FMOC deprotections 
were completed by suspending the resin in 20% piperidine (ChemImpex) in DMF 
supplemented with 0.2 M Oxyma Pure (CEM) and irradiating under variable power to 
maintain a temperature of 90 °C for 60 seconds. Coupling reactions were completed by 
combining the amino acid (5 eq relative to resin; CEM, ChemImpex, and NovaBiochem), 
diisopropylcarbodiimide (7 eq, ChemImpex), and Oxyma Pure (5 eq) in DMF and 
irradiating under variable power to maintain a temperature of 90 °C for 4 minutes. The 
resin was rinsed four times with an excess of DMF between all deprotection and coupling 
steps. 
After synthesizing, resin was coupled with a fluorescein isothiocyanate (FITC) tag. 
95%TFA / 2.5%TIPPS / 2.5% water cocktail solution was used to cleave from resin for 3 
hours. Diethyl ether precipitation was used following resin cleavage. Peptides were 
purified using reverse-phase HPLC (Agilent) in 100mM ammonium acetate and 
acetonitrile as the organic phase. Purified fractions were collected, lyophilized then 
reconstituted in DMSO. Peptide concentration was obtained by UV-Vis spectrometer 
where samples were prepared in 6M guanidinium chloride with a 1:1000 ratio. 
Peptides were synthesized with N-terminal b-alanine (b-Ala) and FITC tagged to the 
following sequences. HPLC purification was done over a 10-50% gradient in acetonitrile 
and 100 mM ammonium acetate solvent system. Correct peptides were identified through 






Erm38-72 FITC b-Ala DLAHDSEELFQDLSQLQEAWLAEAQVPDDEQFVPD 
Erm38-68 FITC b-Ala  DLAHDSEELFQDLSQLQEAWLAEAQVPDDEQ 
ATF6a40-66 FITC bAla DTDELQLEAANETYENNFDNLDFDLDL 
VP16 aH2467-
488 





R466D Forward CTGGACCATCCTTGAGTTATCGAACAAAGGGCCCAG  
 
R466D Reverse CTGGGCCCTTTGTTCGATAACTCAAGGATGGTCCAG 
K411E Forward CTGGAGTGGCAAGAGGAGCCCAAACCTGCCTCA 
K411E Reverse TGAGGCAGGTTTGGGCTCCTCTTGCCACTCCAG 
R538E Forward GGCTTCGTCAACGGCATCGAACAGGTCATCACCAACCTC  
R538E Reverse GAGGTTGGTGATGACCTGTTCGATGCCGTTGACGAAGCC  
Q451E Forward CCAGAAGCTGATCATGGAACTCATCCCCCAGCAG 
Q451E Reverse CTGCTGGGGGATGAGTTCCATGATCAGCTTCTGG 
M523E Forward AAGAAGAAGATCTTCGAAGGCCTCATCCCCTA 
M523E Reverse TAGGGGATGAGGCCTTCGAAGATCTTCTTCTT  
 
 
Direct Binding Experiments 
Direct binding experiments were measured with fluorescence polarization and performed 
in black 384-well plates (Corning) and read using the PHERAStar multi-mode plate 
reader. The fluorescein isothiocyanate (FITC) labeled peptide was diluted to a stock 
concentration of 50 nM. Med25 concentration was diluted by half for the indicated data 
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points. Each well contained a final volume of 20µL with a final concentration of 25 nM. 
The data obtain was analyzed using GraphPad Prism software’s nonlinear regression 





The objectives of our modeling efforts were to predict an ensemble of putative structures 
for the N-terminal predicted helical fragment of VP16(438-454) G450C tethered to the 
Med25 AcID domain C506 via a disulfide Tether. Our modeling was initiated from the 
published NMR coordinates for Med25 AcID (PDB) 2xnf). The protein structure of Med25 
AcID was prepared for simulation in CHARMM using the Multiscale Modeling Tools for 
Structural Biology (MMTSB). VP16 has been shown to form a helical conformation when 
in complex with Med25 AcID, so VP16(438-454) G450C was constructed in CHARMM as 
contiguous helix, which was then patched using DISU patch in CHARMM to Med25 C506 
through the formation of a disulfide bond. Prior to running the implicit solvent simulations, 
Med25 was fixed using harmonic restraints, and the complex was minimized with 1000 
steps of a steepest descent algorithm. Using GBSW implicit solvent, temperature replica 
exchange was implemented using the CHARMM22 force field. These simulations were 
run for a total of 60 ns (2 fs time steps) using 12 replicas, sampling between 280-500 K 
and attempting coordinate exchanges every 5000 steps. The 12 replica trajectories were 
sorted by their respective temperatures, and the last 40 ns of the 280 K trajectories were 
then parsed into 4000 coordinate files. The MMTSB tool cluster.pl was used to cluster 
these structures, using K-means clustering with 1.5 Å RMSD cutoff for the superposed 
 
42 
Ca backbone atoms for all the structures. The root-mean-square fluctuations (RMSF) for 
the las 40 ns of the 280 K trajectory were calculated for each Med25 AcID residue by 
superposing Ca atoms of the coordinate files produced from the simulations. Clustering 
of the 4000 structures from the trajectories resulted in 20 clusters for apo Med25 AcID, 
with the highest populated cluster containing 40% of the structures; the Med25 AcID 
VP16(438-454) G450C complex resulted in 5 clusters, with the highest populated cluster 
containing 72% of the 4000 structures. 
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Chapter 3.  
 
Using Covalent Fragment to Target a Key Dynamic Substructure in Med25 
 
3.1 Abstract 
Covalent probes are advantageous to use against dynamic proteins because they are 
able to stabilize different conformations that could play a key role in recognition and in 
gene expression. The focus of Chapter 3 is the use of covalent fragments to target a 
dynamic substructure of Med25-AcID. These results build from the previously defined 
importance of the positively charged substructures of Med25-AcID for guiding activator 
binding.  The data herein supports a model in which that covalently targeting the domain’s 
loop regions can provide a framework for developing probes for this class of dynamic 
proteins. More specifically we demonstrate that disulfide Tethering methods successfully 
identify fragment probes that target Med25-AcID, stabilize its substructures, and enhance 
the binding of at least one transcriptional activator binding partners. Further, assessment 
of analogs of one fragment revealed that the loop comprising Cys506 likely forms a chiral 
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The screening method of Tethering came about as a way of finding a good fragment 
starting point to develop drugs. This process is a more efficient means of searching a 
binding surface for good small molecule-binding subsites as it identifies weak affinity 
fragments at predetermined positions. This is a suitable approach for coactivator proteins 
because there is no pharmacophore framework for dynamic proteins and because the 
binding surfaces are typically ill-defined. Tethering relies on the reversible covalent bond 
formation between a disulfide-containing fragment molecule and a cysteine-containing 
protein. If there is sufficient affinity of the fragment molecule for the binding surface and 
the disulfide moiety is close enough to the cysteine to undergo an exchange reaction, a 
covalent bond will form. The resulting adduct can then be identified by mass 
spectrometry. Due to the presence of a reducing agent such as b-mercaptoethanol, the 
resulting spectra typically show three species: protein alone, protein + reductant, and 
protein + fragment. The most prevalent will be the protein + fragment species if the 
fragment has inherent affinity for the protein of interest.  
 
 
Figure 3.1 Tethering Schematic. Cysteine containing protein target incubated with 




An example of the successful application of Tethering to dynamic coactivators is 
shown in previous work from the Mapp lab with a domain of the master coactivator 
CBP/p300. The CBP/p300 kinase-inducible domain (KIX) is structurally dynamic and has 
two binding surfaces as does Med25-AcID.11 The transcriptional activators MLL and pKID 
form a ternary complex with KIX, with approximately two-fold enhancement of pKID 
affinity when MLL is prebound.18  To investigate if a small-molecule could alter the 
allosteric network connecting the two binding sites, a Tethering screen was performed on 
four distinct cysteine mutants of KIX, each of which had a cysteine positioned in a distinct 
location around the MLL binding site (Figure 3.2A). From this screen the fragment 1-10 
emerged as one of the leading candidates (Figure 3.2B). As shown in Figure 3.2C, 1-10 
can enhance the affinity of pKID to KIX when the fragment is bound at the N627C site 
and inhibit 2-fold when bound at L664C. In other words, the binding site is malleable such 
that more than one binding pose can accommodate 1-10, each with a distinct functional 
outcome. Structural studies of the 1-10 complexes revealed that the flexible loop rimming 







Figure 3.2 Disulfide Fragment Targets KIX dynamic structure. (A) Cysteine mutations 
placed around the MLL binding site of the KIX domain and screened against a disulfide 
library. (B) Fragment 1-10 was of isolated from the screen as lead fragment. (C) Fragment 
1-10 when tethered to different positions in the MLL site changes the dissociation 
constant. 
 
Despite having a considerably different structure than KIX, Med25-AcID is similarly 
dynamic, with both NMR structural studies and molecular dynamics simulations indicating 
regions of considerable disorder.19 Further, the studies described in Chapter 2 support a 
model in which the most dynamic substructures – including flexible loops - within Med25-
AcID play key roles in both molecular recognition and in allosteric communication 
between binding sites. Med25-AcID has three native cysteines, two of which are 
positioned near flexible loop regions. Cysteine 429, one of the least solvent exposed of 
the three, is angled pointing inside of the β-barrel. The remaining two cysteines are 
solvent exposed, one more than the other. Cysteine 497 is located on the H1 face of the 
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domain pointing into solution and in close proximity to the top loop region and side helix 
substructure of the H1 face. Cysteine 506 is most accessible,  located on the bottom loop 
region. A previous colleague in the Mapp lab, Dr. Andrew Henderson tested the reactivity 
of the cysteines through treatment with an excess of four different iodoacetamide-
containing compounds followed by analysis by mass spectrometry. All four compounds 
have varying percentages of monolabeled species where percentage ranges from 10% 
(iodoacetic acid) to above 80% (iodoacetamide). Fragments 4-iodoacetamidosalicylic 
acid (IAsalicylic acid),  iodoacetamidodimethylbenzne (IAdimethylbenzene), and 
iodoacetamide also double label Med25-AcID. Mutational analysis revealed that cysteine 
506 is the most reactive, cysteine 497 reacts with IAsalicylic acid, and cysteine 429 
showed no reactivity under these conditions, consistent with its lack of surface exposure 
in the structural model.  With reactive cysteines positioned adjacent to and within dynamic 
loop regions, we thus hypothesized that disulfide Tethering could be an effective strategy 
to allosterically regulate Med25 binding and function.   
Figure 3.4  Med25-AcID native cysteine accessibility. (A) Four covalent fragments with 
highly reactive electrophilic groups incubated with Med25. (B) Results from Tethering 
experiments identified by mass spectrometry show Med25-fragment species. Work 




3.3 Results and Discussion 
 
Fragment Discovery in Med25 Using Disulfide Tethering 
Wild-type Med25-AcID was screened against a 1600-member disulfide fragment library 
with the expectation that molecules that selectively label C497 or C506 would be 
identified, as well as have allosteric effects on activator binding.8 This was carried out in 
collaboration with Dr. Jim Well’s lab with postdoctoral fellow Dr. Zachary Hill at UCSF.4,5 
After expression of sufficient quantities of Med25-AcID and identifying appropriate buffer 
conditions for the screen, materials were transferred to UCSF. For the screen 
concentrations of Med25-AcID and fragments were held at 100 µM while two 
concentrations of β-mercaptoethanol (BME) were used, 100 µM and 1 mM. β-
mercaptoethanol concentration was increased to report on the affinity of the Tethered 
species; fragments that remain bound even at 1 mM BME are higher affinity ligands than 
those that only bind with lower concentrations of BME.  Molecules were considered hits 
that bound to Med25-AcID at levels greater than 3 standard deviations above the mean 
with BME concentrations at 100 µM.  
 
 
Table 3.1 The Mass Spectrometry Tethering Screen Results 
  
Original Screen (100 µM Fragment, 1 mM 
BME) 

































































































































After identifying these hits, secondary screening efforts were carried out to identify which 
of the solvent exposed cysteines were being Tethered. To do this, the 24 hits were 
incubated with a Med25-AcID mutant where cysteine 506 was changed to an alanine 
residue. There was minimal tethering occurring at cysteine 497. Compounds such as 10 
and 15 were among the higher tethering percentages which tethered at 20% and above 
more specific to cysteine 497. The low tethering percentages seen on the alanine mutant 










Figure 3.5  Results of the tethering screen with wild-type Med25-AcID and C506C 
mutant. (A) The structure of the 24 hit fragments above 3 standard deviations are 
displayed. (B) This shows the percent tethering of the 24 hits with Med25 wild-type and 
mutant C506A. Screening experiments were carried out Dr. Zachary Hill. 
 
Among the 24 fragments, several structures emerged as particularly interesting due to 
their high Tethering percentage (60%), compounds 2, 4, 5, 11, and 22. Among those 
compounds 2, 4, 11, and 22 showed high selectivity for C506.  In particular, fragment 22 
was found to tether at 75% and is specific to cysteine 506. There was then interest in 
understanding what structural features of the fragment allows for this high tethering 




Targeted Dynamic Substructure Allows for Allosteric Modulation 
After identifying fragment 22, the allosteric effects of fragment 22 were tested by using 
transient kinetic experiments.17,14,12,10,2 The control set of experiments worked where 
Med25-AcID was incubated with the fluorescently labeled DMN VP16 and an acetylated 
version was rapidly mixed in proper stopped-flow procedures.9,16 The florescence read-
out showed a koff value of 517 s-1 . Med25-AcID was tethered to fragment 22 and this 
decreased the koff value to 367 s-1 , an approximately 25% reduction. The same set of 
experiments were carried out using the activator ATF6a.13 The controlled experiment koff 
value was 143 s-1  and protein-fragment complex is 107 s-1 . The observed koff values show 
that there is an increase in the binding of both activators as a result of the fragment 
binding.  
 
Figure 3.6 Fragment 22 alters activator binding to Med25. The bar graph represents a 
comparison of koff values  of activators VP16 and ATF6a with Med25-AcID with fragment 




To probe this question, Dr. Brittany Morgan designed and synthesized derivatives of 
fragment 22 in which the connectivity between the carbonyl and the naphthyl moiety was 
altered. Interests were in this moiety due to its proximity to the naphthyl group and 
possible interactions with the pi system.  Derivatives 22A and 22B addressed the sterics 
of the methyl group. In contrast, fragment 22C is removal of the methyl and 22D is the 
linear fragment with the removal of the central carbon that links the methyl group. This 
set of results shows that fragments 22 and 22A tether at similar single point tethering 
percentages under screening conditions. The fragments 22B, 22C, and 22D tether at 
lower single point tethering. Fragments 22A and 22B results show sterics of the fragments 
methyl group are important and suggests a chiral binding surface. 
 β-Mercaptoethanol titration experiments were also used to rank the tethering efficiency 
of each derivative. The concentrations of Med25-AcID and disulfide fragment were held 
constant, while the β-Mercaptoethanol concentrations were varied. This data shows that 
it takes high concentrations of β-Mercaptoethanol to disassemble the 22 and 22A protein 
fragment complex. These Tethering events are more favorable events because of the 
presence and sterics of the methyl group. In contrast, compounds 22B, 22C, and 22D are 
































Figure 3.7 Tethering efficiency of fragment 22 derivatives. (top row) Derivatives of 
fragment 22 were synthesized with changes to the methyl group. (Bottom row) Single 
point tethering and β-ME50 curves were quantified by mass spectrometry. Experiments 
were done in collaboration with Dr. Brittany Morgan. 
 
Med25-AcID is a coactivator that has dynamic substructures that allow it to interact with 
its binding partners. There have been examples in literature that contribute the changes 
seen in positive and negative cooperative binding to levels of stabilization within proteins.7 
The kinase-inducible domain (KIX) of the CBP  coactivator complex is important in 
regulating transcriptional activity.3 The KIX domain is able to be cooperatively targeted by 
transcription factors and small molecules.6 There are significant changes this domain’s 
stability that help alter activator binding when a small molecule is tethered.15 Here is 
shown that Med25-AcID exhibits levels of stabilization when tethered to a small molecule 





  Half-Life, minutes 
Apo Med25  0.3 ± 0.1 
Med25-22 0.6 ± 0.3 
 
 
Figure 3.8 Signs of Med25-AcID stabilization from fragment 22. This represents 




Med25-AcID coactivator is a part of a difficult class of proteins to target in drug discovery. 
They are usually highly dynamic in nature and bind many different activators using limited 
binding sites. Taking from the findings in the previous chapter, this chapter used covalent 
probes to target the dynamic loop substructure of Med25-AcID. Through tethering 
screens, it identified a fragment that’s selective to the native cysteine 506 that’s located 























communicate with the opposite binding surface.11 This is seen through stopped-flow 
experiments where koff values are decreased with activators ATF6a and VP16. 
Degradation experiments were then carried out to determine there were levels of 
stabilization within the domain that participated in allow this event. Other efforts show 
there are components of the tethered fragment that help create for a successful tethering 
event. The stereochemistry of the methyl group proved to be essential through testing 
derivatives of the fragment. This also allowed us to draw conclusions about the tethered 
surface of Med25-AcID. It a chiral surface area that recognizes the fragment which is 
useful information in future development. 
 
3.5 Materials and Methods 
Plasmids 
The plasmid used to produce Med25(394-543) with a six histidine tag was pET21b. 
Patrick Cramer provided the plasmid.  
 
Protein Expression and Purification 
BL21-AI competent cells were used for transformation steps. Competent cells were 
resuspended and streaked across LB Agar plates containing streptomycin and ampicillin 
antibiotics. The plates were then invubated at 37oC overnight. A colony was picked and 
added to a 50 mL Terrific Broth (TB) starter culture which contained 5 µL of ampicillin 
(100 mg/ml) and streptomycin (50 mg/ml). The next morning,  7mL were used to inoculate 
the 1 liter TB that contained ampicillin and streptomycin. The bacteria was grown at 37oC 
to an OD600 of 0.8. Once optimal OD600 was achieved, 10% arabinose and IPTG was 
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added and incubated at 27oC  at 250 rpm overnight. The 1 liter TB culture was spun down 
to pellet using the floor centrifuge at 5000 rpm for 20 minutes at 4oC. Cell pellets were 
stored at -80oC. Cell pellet was resuspended in lysis buffer (components), b-
Mercaptoethanol, and an EDTA-free protease inhibitor tablet. The suspended cells were 
sonicated and filtered before purification. Sample was purified by FPLC with both Nickel 
(HisTrap, Buffer A: 50 mM sodium phosphate, 300 mM NaCl, and 30 mM imidazole, pH 
6.8  ; Buffer B: 50 mM sodium phosphate, 300 mM NaCl, and 400 mM imidazole, pH 6.8) 
and Ion Exchange columns (Buffer A: 50 mM sodium phosphate, 1 mM DTT, pH 6.8 ; 
Buffer B: 50 mM sodium phosphate, 1 mM DTT, 1 M NaCl, pH 6.8 ). Purified samples 
were collected and dialyzed in 10 mM sodium phosphate and 100 mM sodium chloride. 
The concentration of the resulting Med25 was measured using a Nanodrop at wavelength 
280 nm using the extinction coefficient e=22460 M-1cm-1. 
 
Med25 labeling with disulfide fragments 
The β-ME experiments were carried out at room temperature and quantified by Agilent 
Q-TOF HPLC-MS. Samples were injected on to a C8 Poroshell column. There were data 
points collected over a range of 12 β-ME data points ( 30, 15, 7.5, 3.8, 1.9, 0.94, 0.47, 
0.23, 0.12, 0.059, 0.030, 0.015 mM ). 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡	𝑇𝑒𝑡ℎ𝑒𝑟𝑒𝑑 =
𝑀𝑒𝑑25 − 𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡
(𝑎𝑝𝑜𝑀𝑒𝑑25) + (𝑀𝑒𝑑25 − 𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡) + (𝑀𝑒𝑑25 − βME) 
 
Protein Degradation 
Med25 wildtype and Med25-22 complex solutions were incubated at 60oC with the 
protease thermolysin.1 Thermolysin cleaves proteins at the N-terminus of the hydrophobic 
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residues leucine, phenylalanine, isoleucine, alanine, and methionine. Solutions were 
diluted in proteolysis buffer ( 50 mM Tris-HCl, 100 mM NaCl, 0.5 mM CaCl2 , and 4 M 
Urea ) with a final 1 to 4 molar ratio. The solutions were quenched with EDTA at a final 
concentration of 5 mM. Quantification was by ImageJ from Bis-Tris protein gel bands. 
Protein abundance values were recorded and fit to an exponential decay equation. 
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Chapter 4.  
Conclusions and Future Directions 
 
4.1 Conclusions of this work 
The Mediator complex is an important portion of the pre-initiation complex that contains 
protein-protein interaction networks that are valuable therapeutic targets. The tail region 
of the Mediator complex is one of particular interest because of its association with 
transcription factors4. The transcription factors that associate with the tail module are 
involved in a number of diseases. In a key example that has been the focus of this work, 
the subunit Med25 participates in cancer metastasis through association with the Ets 
transcription factor Erm2. Like many protein-protein interactions, this interaction is thought 
to be “undruggable” due to difficulties of targeting the large and dynamic surface area of 
Med2511. There is thus a lack of therapeutic agents and probes that target coactivator 
Med25-AcID and others like it. 
The work in this thesis was guided by the goal of identifying small molecule 
fragments that target the uniquely folded coactivator subunit Med25, in particular its 
activator binding motif AcID. The hypothesis was that the use of covalent fragments that 
target the dynamic substructure of Med25-AcID would inform a molecular recognition 
model for small-molecule targeting. This was based upon defining important principles of 
the coactivator-activator binding mechanism as shown in Chapter 2. We first determined 
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the important mechanistic features of the coactivator-activator interaction. Next, we 
carried out small molecule screens with a disulfide fragment library with Med25-AcID. 
Experiments were performed that identified the fragment’s necessary characteristics for 
covalent labeling and effects on coactivator conformational dynamics. 
As outlined in Chapter 2, work was done to define  important mechanistic features 
of the Med25 coactivator-activator interaction. One such question was if activators bind 
to different binding surfaces in Med25-AcID, with a particular focus on the ETV/PEA3 
activators, VP16, and ATF6a14,16,17. We first determined where activators bind in the 
domain of Med25-AcID. Earlier HSQC NMR experiments were carried out with Erm and 
VP16,  both H1 face binding activators. Mutagenesis within the AcID domain was guided 
by the shared perturbed residues of the Erm and VP16 HSQC NMR experiments. The 
resulting data revealed ATF6a interacts on a different binding surface in contrast to Erm 
and VP168. HSQC NMR experiments with the ATF6a Med25-AcID complex further 
confirmed its interaction with the H2 face of the domain due to the perturbed residues 
found there. Thus, when planning small molecule targeting of Med25-AcID, there is a 
choice of binding sites to consider. 
We were then interested in the electrostatic contacts of the interaction because 
Med25-AcID is positively charged and its activators are highly negative. This was 
particularly a line of inquiry because electrostatics was an essential component in a study 
done with the CBP Taz 1 domain and binding activators. It found that charge was very 
important in the ternary complex interactions with CITED2 and HIF-1a transcriptional 
activation domains18. Insightful information of the Hoffmeister’s series aided in designing 
the next set of experiments13,15. This series shows the ranking of ions based on their 
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strength to interact with proteins. Residue side chain interactions play a role in its ability 
to bind proteins along with other possible ion interacting mechanisms. Binding 
experiments with cations and anions of different strengths and concentrations show 
electrostatics are important in guiding activator interactions with Med25-AcID. Increasing 
the salt concentration in the assay buffer produces more ions that interrupt Med25-AcID 
activator binding events. Further experiments proved that the size of ions have varying 
effects on this PPI. The overall negative charge of activator Erm was decreased and 
further confirms this point on charge-charge contacts within the interface. From here we 
noticed that many of the positive residues were housed within the flexible substructures 
of the domain and molecular dynamic simulations showed these same regions stabilized 
upon binding activators8. The dynamic substructures were then considered for small-
molecule targeting seeing the H1 face contains thiophilic handles available for covalent 
probes.  
In Chapter 3, we carried out disulfide fragment screening methods5,6. Med25-AcID 
has three native cysteines within the domain. Of the three cysteines, two of them are 
solvent exposed and available for sufficient disulfide exchange. Cysteine 497 is placed in 
close proximity to the top loop region of the H1 face, while cysteine 506 is located on the 
bottom flexible loop region on the same surface. This could prove to be useful seeing 
these regions are important in activation domain binding. This was determined by 
experiments done by Dr. Andrew Henderson. He incubated Med25-AcID with small 
molecule fragments iodoacetamide, iodoacetamidosalicylic acid, 
iodoacetmidodimethylbenzene which all have a thiophilic leaving group. This set of mass 
spectrometry results showed Med25-AcID contained only single and double labeled 
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species present upon incubation. Further mutagenesis studies of cysteine 506 confirmed 
cysteines 506 and 497 are available for disulfide exchange. Screening was done in 
conjunction with the Dr. Jim Wells lab at the University of California San Francisco, where 
Dr. Zachery Hill was our collaborator. The disulfide Tethering method was used to identify 
hits with the use of mass spectrometry quantification. Experiments identified 24 hits that 
were above 3 standard deviations. We were interested in learning where the identified 
fragments labeled after identifying the hits from the initial screen. Building from the 
understanding Med25-AcID has two solvent exposed cysteines, both are located  on the 
H1 face of the AcID domain. Cysteine 506 is located in the dynamic loop region and 
cysteine 497 is on the b -barrel. Expressed aliquots of wild-type Med25-AcID and cysteine 
506 alanine (C506A) mutant were provided. Labeling of Med25-AcID drastically 
diminished with the mutant form of the protein. The two fragments that had moderated 
labeling which included fragments 10 & 15 which targeted cysteine 497.  
Of the two screens, we were most interested in the fragment 22. This was of 
interest because of its ability to single tether at high percentages and specific to cysteine 
506 located in the flexible loop substructure at the base of Med25 AcID. One of the 
advantages of using the Tethering method is that it can stabilize different conformations. 
This is a useful technique in targeting Med25-AcID because of the dynamic nature of the 
substructures found to be important for activator interaction. Experiments were then 
carried out to determine how fragment 22 alters binding of activator proteins. Stopped-
flow kinetics was used to quantify the koff values of the binding activators VP16 and 
ATF6a. Results showed that fragment 22 decreases the koff value of VP16 and ATF6a 
activators8. This also shows that tethering the flexible loop region on the H1 face with 
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fragment 22 is able to change binding at the H2 face of Med25-AcID which is located on 
the opposite surface. Interest was then taken in understanding if the AcID domain was 
more stable in the presence of fragment 22. Apo AcID and AcID-22 complex were 
incubated with thermolysin protease. These results show there is moderate stabilization 
within the domain when fragment 22 is tethered to the flexible loop region. We then 
investigated which features of fragment 22 were essential for causing a successful 
tethering event. Derivatives of the fragment were made by Dr. Brittany Morgan that made 
changes to an important methyl group. Single-Point tethering experiments showed the 
presence and stereochemistry of the methyl group allowed for successful labeling of the 
protein. 
Some of the major findings of this work conclude that the dynamic loop 
substructures of the coactivator Med25-AcID are an essential portion of binding its’ 
associated activation domains. The charged residues of these regions guide interaction 
with a variety of activator proteins. The broader importance of learning the contributions 
of electrostatics has been seen in other coactivator-activator systems. Interactions that 
involve the coactivators Taz 1 and IBiD show examples and make suggestions that 
charge-charge interactions play critical roles in guiding activator binding. Work here also 
shows covalently targeting this region is advantageous because these probes can 
stabilize different conformations that can be effective in coactivator ternary complexes. 
Taken together this can serve as model to target dynamic substructures of coactivator 
proteins. 
 
4.2 Future Directions 
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Electrostatic Selectivity Section 
As talked about in detail in Chapter 2, electrostatics are an important component for 
guiding activators binding to Med25-AcID. The study done with the Taz1 domain in both 
binary and ternary complexes gives insight that determined electrostatic forces are 
essential for displacement of HIF-1a by CITED2. This is interesting because it gives 
insight to what allows inhibitory effects that can be transferred principles in other 
coactivators and small molecule efforts. Taking this into account, this raises the broader 
question of how selectivity is achieved among activator-coactivator interactions. 
Coactivator proteins usually have designated domains that bind a variety of activator 
proteins on limited surfaces. In the coactivator class of proteins, surfaces vary in overall 
charge. Future experiments will include synthesizing control and experimental activator 
peptides that bind Med25-AcID. Experimental peptides will have negative charge 
residues mutated to polar residues that are close in size. For example, glutamic acid (Glu) 
will be changed to glutamine (Gln), and aspartic acid (Asp) will be changed to asparagine 
(Asn). The following changes in to the activator would be thought to effect selectivity of 
peptides to other coactivator domains. The same control and experimental peptides will 
be used to bind other coactivator domains such as the IBiD and KIX domains which are 
a part of the CBP coactivator complex3.  
 
Further Disulfide Fragment Assessment  
The Tethering screen conducted and described in Chapter 3 identified fragment 22 as an 
enhancer of ATF6a binding to Med25. It was identified as being specific in Tethering 
native cysteine 506 located in one of the domain’s dynamic loop regions. This has the 
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ability  to alter the koff values of activators VP16 and ATF6a. There is room for further 
quantification of the effects of the fragment on activator binding. This would include using 
Med25-AcID fragment complex and fluorescently labeled activator peptides to conduct 
fluorescence polarization assays. Binding affinities will be calculated where we would 
expect to see signs of increased. This would be expected because there have been 
previous studies on the CBP KIX domain that suggest stabilization of the domain can 
cause this type of change increased affinity.  
 In addition, the cell has a highly reducing environment. The fragment 22 currently 
exists in the reversible form which can easily be reduced. Fragment 22 would need to be 
converted to an irreversible form for engaging its’ target in cells7,9. There are an array of 
electrophilic leaving groups that can be used. Electrophilic groups vary in reactivity and 
selectivity. For example, electrophiles such as chloroacetamide and 
bromodihydroisoxazoles are usually specific to cysteine residues where chloroacetamide 
is more reactive (electrophilic) than bromodihydroisoxazoles.  
There were other interesting fragments identified from the screen that specifically 
targeted cysteine 497. Fragment 10 tethered at 15% to apo Med25-AcID. The same 
fragment labeled the cysteine 506 alanine mutant at higher percentages. This could be 
done as a comparative study on the effects of binding when targeting different 
substructure types. 
Upon converting fragment 22 from a reversible to an irreversible form, the genes 
associated with Med25-activator protein-protein interactions. There is an association of 
HSP5a gene with the activator ATF6a, while the matrix-metalloprotease 3 with Erm1,16. 
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There can also be qPCR experiments that monitor expression levels of Erm and ATF6a 




1. Baert, Jean-Luc, et al. “Expression of the PEA3 Group of ETS-Related 
Transcription Factors in Human Breast-Cancer Cells.” International Journal of 
Cancer, vol. 70, no. 5, 1997, pp. 590–97, doi:10.1002/(SICI)1097-
0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H. 
2. de Launoit, Yvan, et al. “The Ets Transcription Factors of the PEA3 Group: 
Transcriptional Regulators in Metastasis.” Biochimica et Biophysica Acta (BBA) - 
Reviews on Cancer, vol. 1766, no. 1, Aug. 2006, pp. 79–87, 
doi:10.1016/j.bbcan.2006.02.002. 
3. Dyson, H. Jane, and Peter E. Wright. “Role of Intrinsic Protein Disorder in the 
Function and Interactions of the Transcriptional Coactivators CREB-Binding 
Protein (CBP) and P300.” Journal of Biological Chemistry, vol. 291, no. 13, Mar. 
2016, pp. 6714–22, doi:10.1074/jbc.R115.692020. 
4. El Khattabi, Laila, et al. “A Pliable Mediator Acts as a Functional Rather Than an 
Architectural Bridge between Promoters and Enhancers.” Cell, vol. 178, no. 5, 
Elsevier, Aug. 2019, pp. 1145-1158.e20, doi:10.1016/j.cell.2019.07.011. 
5. Erlanson, Daniel A., Andrew C. Braisted, et al. “Site-Directed Ligand Discovery.” 




6. Erlanson, Daniel A., James A. Wells, et al. “Tethering: Fragment-Based Drug 
Discovery.” Annual Review of Biophysics and Biomolecular Structure, vol. 33, no. 
1, Annual Reviews, May 2004, pp. 199–223, 
doi:10.1146/annurev.biophys.33.110502.140409. 
7. González-Bello, Concepción. “Designing Irreversible Inhibitors—Worth the 
Effort?” ChemMedChem, vol. 11, no. 1, John Wiley & Sons, Ltd, Jan. 2016, pp. 
22–30, doi:10.1002/cmdc.201500469. 
8. Henderson, Andrew R., et al. “Conservation of Coactivator Engagement 
Mechanism Enables Small-Molecule Allosteric Modulators.” Proceedings of the 
National Academy of Sciences, vol. 115, no. 36, Sept. 2018, p. 8960, 
doi:10.1073/pnas.1806202115. 
9. Jöst, Christian, et al. “Promiscuity and Selectivity in Covalent Enzyme Inhibition: 
A Systematic Study of Electrophilic Fragments.” Journal of Medicinal Chemistry, 
vol. 57, no. 18, American Chemical Society, Sept. 2014, pp. 7590–99, 
doi:10.1021/jm5006918. 
10. Landrieu, Isabelle, et al. “Characterization of ERM Transactivation Domain 
Binding to the ACID/PTOV Domain of the Mediator Subunit MED25.” Nucleic 
Acids Research, vol. 43, no. 14, Aug. 2015, pp. 7110–21, 
doi:10.1093/nar/gkv650. 
11. Mapp, Anna K., et al. “Targeting Transcription Is No Longer a Quixotic Quest.” 




12. Milbradt, Alexander G., et al. “Structure of the VP16 Transactivator Target in the 
Mediator.” Nature Structural & Molecular Biology, vol. 18, no. 4, Apr. 2011, pp. 
410–15, doi:10.1038/nsmb.1999. 
13. Okur, Halil I., et al. “Beyond the Hofmeister Series: Ion-Specific Effects on 
Proteins and Their Biological Functions.” The Journal of Physical Chemistry B, 
vol. 121, no. 9, American Chemical Society, Mar. 2017, pp. 1997–2014, 
doi:10.1021/acs.jpcb.6b10797. 
14. Sela, Dotan, et al. “Role for Human Mediator Subunit MED25 in Recruitment of 
Mediator to Promoters by Endoplasmic Reticulum Stress-Responsive 
Transcription Factor ATF6α.” Journal of Biological Chemistry, vol. 288, no. 36, 
Sept. 2013, pp. 26179–87, doi:10.1074/jbc.M113.496968. 
15. Sheinerman, Felix B., et al. “Electrostatic Aspects of Protein–Protein 
Interactions.” Current Opinion in Structural Biology, vol. 10, no. 2, Apr. 2000, pp. 
153–59, doi:10.1016/S0959-440X(00)00065-8. 
16. Verger, Alexis, et al. “The Mediator Complex Subunit MED25 Is Targeted by the 
N-Terminal Transactivation Domain of the PEA3 Group Members.” Nucleic Acids 
Research, vol. 41, no. 9, May 2013, pp. 4847–59, doi:10.1093/nar/gkt199. 
17. Vojnic, Erika, et al. “Structure and VP16 Binding of the Mediator Med25 Activator 
Interaction Domain.” Nature Structural & Molecular Biology, vol. 18, no. 4, Apr. 
2011, pp. 404–09, doi:10.1038/nsmb.1997. 
18. Wang, Yanming, and Charles L. Brooks III. “Electrostatic Forces Control the 
Negative Allosteric Regulation in a Disordered Protein Switch.” The Journal of 
 
76 
Physical Chemistry Letters, vol. 11, no. 3, American Chemical Society, Feb. 













Appendix A. Characterization of Synthesized Peptides 
 
 
Analytical trace of FITC-ERM38-72 monitored at wavelengths 280nm and 214nm. Samples 
were run in a 100mM Ammonium Acetate and Acetonitrile system.  







 DAD1 A, Sig=280,4 Ref=off (NICK\ERM38-72_BALA-FITC_13NOV2019 2019-11-13 14-15-17\001-0101.D)














Analytical trace of FITC-VP16aH2467-488 monitored at wavelengths 280nm and 214nm. 




Analytical trace of FITC-ERM38-68 monitored at wavelengths 280nm and 214nm. 
Samples were run in a 100mM Ammonium Acetate and Acetonitrile system. 
 
 









 DAD1 A, Sig=280,4 Ref=off (NICK\18NOV2019_VP16AH2-BALA-FITC_RIGHT 2019-11-18 16-48-44\001-0101.D)















Analytical trace of FITC-ATF6a38-64 monitored at wavelength 495nm. Samples were run 
in a 100mM Ammonium Acetate and Acetonitrile system. 
 
 
Analytical trace of FITC-ERM38-68 monitored at wavelength 430nm. Samples were run in 
a 100mM Ammonium Acetate and Acetonitrile system 
 
 
Mass Spectrometry spectra of  FITC-ERM38-68 E-to-Q. The peptide was quantified using 















Appendix B. NMR Chemical Shift Perturbations 
 
 
CSP mapping of Med25 AcID upon titration with 3 eq of ERM(38-68). The dotted lines 
indicate chemical shift changes that are one (lower line) or two (upper line) standard 




CSP mapping of Med25 AcID upon titration with 1.0 eq of ATF6a(38-64). The dotted lines 
indicate chemical shift changes that are one (lower line) or two (upper line) standard 
deviations above the average chemical shift change.  
 
 
